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“A PROSPECTIVE RANDOMIZED CONTROL STUDY 
ON INTRACUFF ALKALIZED LIGNOCAINE REDUCES 
SEDATIVE/ANALGESIC REQUIREMENTS FOR 
MECHANICALLY VENTILATED PATIENTS IN A 
TERTIARY CARE HOSPITAL”  
ABSTRACT 
OBJECTIVES: 
This study is to investigate the effect of intracuff alkalised Lignocaine in 
reducing the requirement of analgesia in post-operative patients requiring ventilator 
support and also to analyse patient-ventilator interaction. 
MATERIALS AND METHODS: 
This prospective randomised control study was conducted at the Institute of 
Anaesthesiology, Madras Medical College, Chennai. The study population included 
fifty patients. Patients were randomly assigned into two groups Group A and Group B. 
Group A (Intervention group) were administered intracuff alkalised Lignocaine 
(4% Lignocaine + 8.4% Sodium bicarbonate). Group B (Control group) were 
administered intracuff normal saline. All fifty patients were given Fentanyl infusion in 
a dose of 75µg/hr. The total requirement of fentanyl (25µg) bolus dose, when the 
patients Behavioural pain Scale was ≥5 was calculated during the first 24 hours. 
  
RESULTS: 
The requirement of Fentanyl bolus dose in patients with intracuff Lignocaine 
was less than that of the control group who were administered intracuff normal saline. 
The frequency of cough and ineffective trigger was lower in patients with intracuff 
alkalised Lignocaine compared to patients with intracuff normal saline.  
CONCLUSION: 
This study has documented significant reduction in the requirement of 
analgesia in patients with intrauff alkalised Lignocaine and also decreased frequency 
of ineffective trigger which implies better endotracheal tube tolerance and patient 
compliance. 
KEY WORDS: 
Endotracheal tube cuff tolerance, intracuff alkalised Lignocaine, Fentanyl 
bolus. 
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INTRODUCTION 
Endotracheal tube (ETT) is a source of discomfort and pain in post 
operative mechanically ventilated intensive care unit (ICU) patient who 
have to keep the ETT for a long time. Endotracheal tube discomfort is 
primarily caused by cuff irritation that enhance airway secretions and 
hence, exacerbates cough and produces more discomfort. Sedatives and 
analgesics are usually administered in order to keep the patients in 
comfortable state, especially in the first few Postoperative days  
Usage of Lignocaine hydrochloride with or without addition of 
sodium bicarbonate (i.e., alkalization) for inflating the cuff of 
endotracheal tube instead of air has been studied during general 
anesthesia.. Continuous diffusion of intracuff alkalized Lignocaine across 
the cuff wall, anesthetize the tracheal mucosa and also reduction in the 
ETT-induced emergence phenomena has been documented8. 
The present study is to analyze the effect of intracuff instillation of 
alkalized Lignocaine instead of air on analgesic requirement for post 
operative patient on ventilator support. Also monitor the patient ventilator 
interaction.  
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AIMS & OBJECTIVES: 
1. To investigate the effect of intracuff alkalized Lignocaine on 
analgesic requirement for post-operative patients on 
ventilator. 
2. To monitor the patient-ventilator interaction following the 
administration of intracuff Lignocaine. 
. 
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HISTORY OF LIGNOCAINE 
Lignocaine was discovered from systematic investigations at the 
Institute of Chemistry at Stockholm University (StockholmsHo¨gskola), 
Stockholm. When in early 1930s, Hans von Euler-Chelpin, Ph.D. (1873–
1964, Nobel Prize winner in 1929 for studies on the fermentation of 
alcohols), investigated chemical relationship and inheritance of genes and 
enzymes purely on chemical terms.  
He was analyzing chemical differences between normal barley and 
some chlorophyll-defective mutants which were resistant to certain pests. 
These mutants were obtained from the famous Swedish plant and 
geneticist, H. Nilsson-Ehle,Ph.D. VonEuler-Chelpin et al. isolated an 
alkaloid, an indole, that they named gramine after the Latin name of the 
grass family Gramineae. 
In von Euler-Chelpin’s laboratory, Holger Erdtman, was given the 
task to synthesize a compound, (2-dimethylaminomethylindole) which 
was quiet different from Gramine, but it was an isomer, called 
isogramine. He tested the substance on his tongue, which he found 
anesthetized. This property was not present in Gramine. 
Erdtman, along with a young chemistry student, Nils Lo¨fgren 
prepared several analogs, for the synthesis of isogramine, (dimethyl 
amino acetotoluidide). 
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Pharmaceutical tests of these compounds were performed in von 
Euler-Chelpin’s laboratory with the assistance of his son, Ulf von 
Euler.The compounds were unable to compete with procaine, and the 
investigations were discontinued16. 
After some years, Lofgren continued the interrupted work. In 1943, 
Lofgren gave a compound to his assistant, Bengt Lundqvist who, in self-
experiments, found that the compound to be active and also had a longer 
duration of action than procaine. It was originally labeled LL30 after the 
initials of the two main coworkers. It differed from one of the compounds 
prepared by Erdtman and Lofgren only by the addition of an extra methyl 
group in the 6th position of the benzene ring19. 
Torsten Gordth started the official clinical trials of LL30 way back 
in 1944. It was tested on his students and patients..Leonard Goldberg, 
performed the initial pharmacological and toxicity work. LL30 was tested 
for 3 years before its use was sufficiently convinced. Toxicity test was 
compared with procaine10,11. 
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LL30 was first given to produce intra cutaneous wheals and then 
subcutaneously. The analgesia was tested with the point of a needle. 
TorstenGordh’s wife, Ulla Gordh, at that time a medical student was 
given eight different solutions with their identities concealed. She raised 
wheals by injecting them from eight different glass syringes. To indicate 
which injection was which, she made circles at the injection site and 
numbered it. It was observed that some of the marks quickly disappeared, 
within 15 minutes or so. But one injected site from one particular syringe, 
showed much larger anaesthetised area. This was the one that turned out 
to be Xylocaine. It started working quickly and lasted for a longer 
duration. And additionally had low toxicity. 
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The Karolinska Institute conducted surgical clinic for military at 
the time of war. So Xylocaine was tested on the volunteers. Its effects 
lasted longer than Procaine. 175 subcutaneous skin wheal tests were 
performed in volunteers. The concentrations of Lignocaine varied from 
0.1 to 2%, with and without the addition of adrenaline,1:100,000. The 
mean duration of effect of 25 tests per concentration was reported. It was 
compared with the effect of procaine. Seventy-five intracutaneous wheal 
tests were also performed. After these initial tests, clinical applications 
were started. 
A full anesthetic effect was usually seen after 2 min. Xylocaine 
was tested in 100 patients for pain treatment, with infiltration, extradural 
analgesia, and blocks of the sympathetic system, in which a long lasting 
alleviation of pain was obtained. This effect was not be obtained by any 
other usual local anesthetics. Lignocaine was also attempted for spinal 
anesthesia in a 2% solution.  
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PHARMACOLOGY OF LIGNOCAINE AND FENTANYL 
Lignocaine 
Chemistry :13,32 
 
 
Chemically Lignocaine is Diethyl amino 2, 6 acet-oxylidide 
C14H22N2O  
The molecular weight of the base is 234 and of hydrochloride salt 
is 270 
Lignocaine produces faster, more intense, longer-lasting, and more 
extensive anaesthesia compared to an equal concentration of procaine. 
Lignocaine is used as an alternative choice for individuals sensitive to 
ester-type local anesthetics. 
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Physical property of Lignocaine:32 
 It is a very stable compound, not decomposed by boiling, acid or 
alkalies withstanding, repeated autoclaving.  
 It is colourless , crystalline solid that is readily soluble in water. The 
hydrochloride salt of Lignocaine in water has PH 6.5. 
 The pKa of Lignocaine is 7.72.At the normal PH 7.4 approximately 
65% of lognocaine exists in the charge cationic form,where 35% 
exists in un changed base form  
 Lignocaine has moderate potency, Rapid onset and moderate 
duration of action, with good penetrative power and rapid onset of 
action. It is effective by all routes of administration. 
 Adrenaline prolongs the action of Lignocaine and also reduces the 
rate of it’s systemic absorption. 
Preparation of Lignocaine: 
1. Topical forms: 
Topical spray : 4% and 10% solution 
Gel 2% and 2.5% 
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2. Parentral form:  
0.5%,1%,2% and 4% as Lignocaine hydrochloride. Lignocaine is 
also available along with adrenaline 1 in 1,00,000 and 1 in 2,00,000 
concentrations 
Pharmacokinetics:32 
 At the plasma concentration of 2µg/ml approximately 65% bound 
with plasma proteins. The hepatic excretion ratio is 65.70% and 
plasma half life is 1.6 hours. 
 The volume of distribution of Lignocaine is 1.3 liter/hour. 
 The liver microsomal enzymes and oxydase ,amylases metabolizes 
it. 
 The main pathway in man appears to be by oxydative – de 
alkylation of monoethyl glycine xylidide to 2,6 xylidine. 2,6 
xylidne is hydrolysed to 4 hyroxy 2,6 xylidine. 
 The metabolites are excreted through kidney. 
 Lignocaine is de-alkylated in the liver by CYPs to 
monoethylglycinexylidide and glycine xylidide, which can be 
metabolized further to monoethylglycine and xylidide. Both 
monoethylglycinexylidide and glycine xylidide retain local 
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anesthetic activity. In humans, approximately 75% of the xylidide is 
excreted in the urine as the further metabolite 4-hydroxy-2, 6-
dimethylaniline (Arthur, 1987). 
Pharmacodynamics: 
Local effects: 
 Lignocaine blocks the conduction impulses in the nerve fibres at the 
site of the injection by blocking sodium channels. 
 Sensory motor fibres are inherently equally sensitive to Lignocaine. 
 Smaller fibres and long myalinated fibres are blocked more easily 
than un myalinated fibres . 
 Autonomic fibres are more susceptible than somatic fibre 
Additions of vasoconstrictors eg Adrenaline(1 in 50,000 to 1 in 
2,00,000) 
 Prolongs the duration of action of Lignocaine by decreasing the 
rate of removal from the local site of injection site into the general 
circulation. 
 Reduces the systemic toxicity by decreasing the rate of absorption 
and keeping the plasma concentration lower. 
 11 
 It is very effective surface anesthaetic .it gets rapidly absorbed 
from the mucosal surface.  
 The peak blood concentration achieved with in 4 to 5 minutes after 
instillation.  
SYSTEMIC EFFECTS 
Cardiovascular effects: 
 Heart : Lignocaine is the class1 b anti arrhythmic drug. It suppress 
the automatic ectopic foci by antagonizing the phase 4 
depolarisation in the Purkinji fibres. It does not depress the SA 
node automaticity 
 The rate of phase 0 depolarization not decreased except in the 
presence of hyperkalemia. Lignocaine markedly decrease the 
action potential duration and effective refractory period in the 
Purkinji fibres and ventricular muscles. But conduction velocity is 
not decreased. At therapeutic plasma concentration of 3-5µg/ml , it 
causes little depression in the cardiac contractility 
 Lignocaine is widely used for ventricular arrhythmias in a dose of 
1-2 mg/kg bolus intravenously followed by 2-4 mg/min infusion. 
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Vascular smooth musles: 
 Lignocaine exists a two isomers and ability to provide 
vasoconstriction appear rested in one of these isomers. Hence 
Lignocaine produces vasoconstriction in low dose and vaso 
dilation in high dose. 
 At the dose >75mg/kg/min with plasma concentration > 20µg/min 
Lignocaine can cause asystole and cardiovascular collapse.  
Central nervous system: 
 It readily crosses blood brain barrior causing CNS stimulation 
followed by depression with higher doses. 
 The severity of CNS effects correlate with plasma concentration 
 CNS is more susceptible to the toxic effect than CVS 
 Objective sings of CNS is excitatory in nature many cause 
shivering , muscular twitching and convulsions . It is due to 
blockade of inhibitory pathways at limbic or higher centre in 
cerebral cortex. 
 It has been shown to posses’ analgesic property when given 
intravenously. 
 Reduction of MAC of inhalational anesthatic agent is used as an 
index of its central analgesic property. 
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Neuro muscular junction: 
 It can affect the transmission at the neuro muscular junction and 
hence potentiate the effect of depolarizing and non depolarizing 
mucle relaxant. 
Dosage : 
 The safe dose limit for Lignocaine has been much disputed. The 
factors governing the dosage are weight of the patients and 
different absorption rate from various sites of the injection. 
 The maximum safe dose is 3 – 5 mg/kg without epinephrine , 7 
mg/kg with epinephrine. 
 Concentration of 0.25% - 0.5 % Lignocaine is used for infiltration. 
 A concentration of 1.5 to 2% solution of Lignocaine is used for 
epidural anangesia 
 A concentration of 4% Lignocaine is used for spraying. 
 A concentration of 2 % Lignocaine is used in topical application. 
Clinical uses of Lignocaine: 
 A Lignocaine transdermal patch (LIDODERM) is used for relief of 
pain associated with post herpetic neuralgia. An oral patch 
(DENTIPATCH) is also available for application to accessible 
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mucous membranes of the mouth prior to superficial dental 
procedures. 
  The combination of Lignocaine (2.5%) and prilocaine (2.5%) in an 
occlusive dressing (EMLA) is used as an anaesthetic agent prior to 
venipuncture, skin graft harvesting, and infiltration of anaesthetics 
into genitalia.  
 Lignocaine in combination with tetracaine (PLIAGLIS) in a 
formulation that generates a "peel" has been approved for topical 
local analgesia for usage prior to superficial dermatological 
procedures such as filler injections and laser-based treatments. 
  Lignocaine in combination with tetracaine is marketed in a 
formulation that generates heat upon exposure to air (SYNERA), 
which is presently used before to venous access and superficial 
dermatological procedures like excision, electrodessication, and 
shave biopsy of skin lesions. The mild warming is intended to 
increase skin temperature by up to 5°C for the purpose of 
enhancing distribution of local anaesthetic into the skin. 
Other Uses of Lignocaine: 
 Used in the treatment of Cardiac dysarrythmias, Ventricular 
fibrillation. 
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 A 5% ointment and 2% jelly are used for surface application and 
for lubrication of endotracheal tube and and oscopy instruments. 
 When given topically on cornea, it causes mydriasis, 
vasoconstriction and cycloplegia. 
 Used in the management of neonatal convulsions, 
 For treatment of chronic pain syndrome in adults. 
  It also posses anti-inflammatory, anti-thrombotic activity.  
Adverse effects: 
 Systemic reaction to Lignocaine primarily involve the CNS and 
CVS. 
 The CNS is more susceptible to action of Lignocaine. 
 Sudden cardiac arrest ,coma, cardio-respiratorye collapse may 
occur. 
 Metabolism of Lignocaine may give rise to the formation of 
methaemoglobin ,the average peak concentration being 0.8%, 
ensuing 4-6 hours after injection. Cyanosis is rare. 
  Lignocaine is reported to trigger malignant hyperthermia 
 Neurological damage can occur leading to Cauda equine Syndrom. 
 High plasma levels can cause bradycardia and hypotenion 
 Increase in dose leads to drowsiness, tinnitus, dysgeusia, dizziness, 
and twitching 
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  Clinically significant cardiovascular depression invariably occurs 
at serum Lignocaine levels that produce marked CNS effects. The 
metabolites monoethyl glycinexylidide and glycine xylidide may 
contribute to some of these side effects. 
 The other adverse effects of Lignocaine which are seen with 
increasing dose include drowsiness, tinnitus, dysgeusia, dizziness, 
and twitching. With the increases in dose, seizures, coma, and 
respiratory depression and arrest will be produced. 
 Clinically significant cardiovascular depression invariably occurs 
at serum Lignocaine levels that produce marked CNS effects. The 
metabolites monoethylglycinexylidide and glycine xylidide may 
contribute to some of these side effects.  
 
Pharmocology of Fentanyl:13,32 
Fentanyl is a synthetic opioid which is lipophilic in nature. It acts 
as a µ receptor agonist and has rapid onset of action which lasts for a 
moderate period of time. 
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Chemistry: 
It is a phenylpiperidine derivative. 
The chemical name is N-{1-Phenethyl-4-piperidyl}propionanilide 
citrate. 
 
C22H28N 2OC6H8O7 
 
Molecular weight is 528.5 Daltons 
pKa is 8.43 
The solubility of Fentanyl in alcohol is 1 in 140 and in water 1 in 
40. 
Octornal/water partition co efficient of Fentanyl is 955 
Pharmacokinetics32: 
 A three compartmental model is typically used to describe 
plasma Fentanyl concentration delay.  
 The lung exert a significant first pass effect and transiently take 
up approximately 75% injected dose of Fentanyl. Fentanyl’s 
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volume of distribution is high(3-6 l.kg-1) and clearance also high 
(10-20ml/kg/min ). 
 Approximately 80% of Fentanyl is bound to plasma proteins, 
and significant amount (40%) is taken up by red blood cells. As 
the pKa of Fentanyl is high(8.4) at physiological PH, it exists 
mostly in the ionized form (>90). 
 Fentanyl is the highly lipid soluble, a finding that explains in 
parts its large volume of distribution, The tissue/blood partition 
co efficient of Fentanyl is found to be 2-30 fold higher than 
those of aFentanyl. Fentanyl is distributed so widely in the body 
must finaly return to the body to get metabolized in the liver. 
 Fentanyl is relatively long acting in large part because of its 
wide spread distribution in the body tissues. Fentayl is 
metabolized in the liver by N-dealkylation and hydroxylation. 
Fentanyl also have high hepatic clearance and high hepatic 
excretion ratio.  
 The primary metabolite is nor Fentanyl which is detectable in the 
urine at least for 48 hours after intra venous Fentanyl 
administration .But activity of Fentanyl metabolites is unclear, 
but it thought to be minimal. A minimal amount of Fentanyl is 
excreted unchanged form in the urine.  
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Pharmacodynamis: 
 Fentanyl is the µ agonist.It has more rapid onset and shorter 
duration of action than morphine. 
 The greater potency and more rapid onset of the action reflect 
the greater lipid solubility of Fentanyl compared with the 
morphine.  
 Fentanyl produces the dose related analgesia. Small doses 0.5-
3.0µgs/kg may be used as supplement in spontaneously 
breathing anaesthetized patient. The dose of 5.0µgs/kg will 
suppress the somatic and autonomic response to surgical 
stimulation in ventilated patients. 
 Fentanyl is potent respiratory depressant and reduces the brain 
stem respiratory centre responsiveness to carbon dioxide and 
peripheral chemoreceptor input during hypoxemia. 
 Fentanyl exert minimal effect on circulation. There is vagaly 
mediated brady cardia and slight fall in the systemic vascular 
resistance.  
 Skeletal muscle rigidity (woody chest ) and clonic movement 
can hinder mechanical ventilation. The effect is reversed by the 
naloxone and overcome by the neuro muscular blocking drugs. 
Rigidity may also occur during emergence from anaesthesia. 
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 Fentanyl causes nausea and vomiting due to the stimulation of 
chemo receptor trigger zone. Fentanyl cause cough , papillary 
muscles constriction and itching of the nose. 
 Fentanyl has been known to increase the inra cranial pressure in 
patient with severe head injury.Fentanyl also significantly 
decreases cerebral perfusion pressure. 
Alkalized Lignocaine: 
Alkalized Lignocaine is a mixture of Lignocaine 2% (Xylocaine) 
and sodium bicarbonate (NaHCO3) 8.4% at a ratio of 1:1 ml. Increasing 
the PH of the solution predictably increase the percentage of non-ionized 
fraction of the drug. Addition of the bicarbonate causes 63 fold increase 
in the diffusion of Lignocaine across the ETT cuff. 
Diffusion of Lignocaine across the ETT cuff may enable the cuff to 
serve as reservoir of local anesthetics and subsequent anaesthesia of 
underlying local mucosa, by blocking cough receptors or rapidly adopting 
stretch receptors. 
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ANATOMY OF LARYNX29 
 The larynx is the organ of phonation; it also assists in coughing and 
straining, and closes the respiratory system during swallowing, 
preventing aspiration.  
 It develops from the fourth and sixth bronchial arches. At the level of 
C3toC6, it is smaller and slightly higher in adult females than in adult 
males.  
 There are nine cartilages in the larynx, but the hyoid is the only bone. 
The U-shaped hyoid bone suspends the rest of the larynx. It does not 
directly articulate with any other bone; instead, it connects to the 
styloid process of the temporal bones by the stylohyoid ligament, and 
to the thyroid cartilage by the thyrohyoid membrane and muscle.  
 The hyoid has a body, and greater and lesser horns, or cornua. The 
laryngeal cartilages consist of the solitary thyroid, cricoid and 
epiglottis, and pairs of arytenoids, corniculates and cuneiforms. They 
are connected by joints and ligaments, which are known as folds 
when covered by mucous membrane.  
 The leaf-shaped epiglottis is situated between the superior laryngeal 
inlet and the base of the tongue. It is connected to the hyoid bone by 
the hyo-epiglottic ligament. Between the epiglottis and the base of the 
tongue is a pouch-like fold called the vallecula. It is into this that the 
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tip of the correctly placed laryngoscope is inserted during direct 
laryngoscopy in adults.  
 
 
  
 23 
 
 
 The shield-like thyroid cartilage is formed from the fusion of two 
quadratic laminae. The angle of fusion is more acute in the male (90) 
than in the female (120), which causes the vocal cords to be longer in 
the male, accounting for the deeper voice and the greater laryngeal 
prominence (Adam’s apple) in men.  
 The superior cornu of the thyroid cartilage is attached to the lateral 
thyrohyoid ligament, and the inferior cornu articulates with the 
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cricoid cartilage at the cricothyroid joint. It is the articulation at this 
joint that maintains the tension with varying length of the vocal cords. 
The cricoid cartilage is shaped like a signet ring at the base of the 
larynx. Since it is relatively strong, and is the only complete ring of 
cartilage in the airway, it is here that Sellick’s manoeuvre is 
performed to prevent regurgitation during rapid-sequence induction. 
Its anterior component connects to the thyroid by the cricothyroid 
membrane, an avascular structure.  
 The arytenoid cartilages are in the posterior part of the larynx, and are 
shaped like three-sided pyramids. They articulate with the cricoid 
cartilage and control the tension of the vocal cords .  
 The arytenoid cartilages connect with the epiglottis via the 
aryepiglottic folds. The cuneiform and corniculate cartilages are 
embedded in the aryepiglottic folds between the epiglottis and 
arytenoids. They reinforce the folds and may assist in movement of 
the arytenoids. The cuneiforms are cylindrical and are anterolateral to 
the triangular corniculates. They can be seen as raised areas in the 
folds during laryngoscopy . 
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  Vocal cords The vocal cords are made from the free upper edges of 
the cricothyroid membrane (conus elasticus) where it thickens to 
become the cricovocal ligament and is covered with mucosa. The 
mucosa is pearly white and has no submucosa; thus, it cannot become 
oedematous. Posteriorly, it is attached to the vocal process of the 
arytenoid cartilage, which forms the posterior 40% of the cords. The 
cricothyroid membrane is attached circumferentially around the 
inside of the ring of the cricoid cartilage, and has a free upper inner 
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margin which is attached anteriorly to the back of the thyroid via a 
membrane called Broyle’s ligament cartilage, and posteriorly to the 
arytenoids. It is this free margin which forms the cords themselves.  
 Muscles: The muscles can be divided into intrinsic and extrinsic 
muscles. 
  The extrinsic muscles can be further divided into suprahyoid muscles 
(stylohyoid, geniohyoid, mylohyoid, thyrohyoid digastric and 
stylopharyngeus), which can elevate the larynx, and infrahyoid 
muscles (omohyoid, sternothyroid, sternohyoid and thyrohyoid), 
which lower the larynx and to a minor degree alter the laryngeal 
shape. 
  The intrinsic muscles control the vocal cords . All intrinsic muscles 
of the larynx are supplied by the recurrent laryngeal nerve except for 
the cricothyroid, which is supplied by the external branch of the 
superior laryngeal nerve.  
 The cricothyroid is the only muscle that tightens the cord and it is 
supplied by the external branch of the superior laryngeal nerve is an 
intrinsic muscle of the larynx, but lies outside the larynx. 
  Nerve supply29: Nerves supplying the intrinsic muscles and 
sensation to the larynx originate from the vagus, via the superior and 
recurrent laryngeal nerves. The superior laryngeal nerve separates 
from the vagus just outside the jugular foramen, at the inferior vagus 
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ganglion. At the level of the hyoid, it subdivides into internal and 
external branches. The internal branch passes through the thyrohyoid 
membrane and provides sensory innervation up to the vocal cords; the 
external branch supplies the cricothyroid muscle. The recurrent 
laryngeal nerve branches from the vagus in the thorax and loops 
around the arch of the aorta on the left and the subclavian artery on 
the right before travelling back up between the oesophagus and the 
trachea to supply all the intrinsic muscles of the larynx except the 
cricothyroid and sensation to the larynx below the vocal cords. 
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 The blood supply : blood supply derived from the external carotid, 
which gives off the superior and inferior thyroid arteries, which 
themselves give off the superior and inferior laryngeal arteries. The 
subclavian artery also supplies the larynx.  
 The trachea : The trachea is an elastic structure which stretches on 
inspiration. It is formed by C-shaped cartilaginous incomplete rings, 
with the defect posteriorly, joined together by the trachealis muscle 
and is supplied by the inferior thyroid artery and veins and the 
bronchial arteries. Nerve supply is from the vagus and recurrent 
laryngeal nerves for pain and secreto-motor functions, and from the 
sympathetic nerves to blood vessels and smooth muscle.  
Relations:  
 Anterior: inferior thyroid veins, anterior jugular arch, inferior 
mesenteric artery, thymus, sternum, sternohyoid, sternothyroid, left 
brachiocephalic veins. 
  Posterior: oesophagus, recurrent laryngeal nerves.  
 Lateral: carotid sheath, lateral lobes of the thyroid to the sixth ring. 
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Cricothyrotomy and tracheostomy 
 A cricothyrotomy is made by making a slit or small hole anteriorly in 
the relatively avascular cricothyroid membrane. A formal 
tracheostomy is made in the second or third tracheal ring by cutting a 
hole, often after dividing the thyroid isthmus if done surgically. The 
inferior thyroid veins and brachiocephalic vessels can get in the way 
and make this difficult.  
  Bronchi : The right and left main bronchi differ from each other in 
the following ways: right: wider, shorter, more vertical, 2e3 cm long 
left: narrower, longer, more horizontal, 5 cm long.  
This is the basis for two clinical points:  
1. Inhaled foreign bodies are more likely to enter the right main 
bronchus. 
2. The correct placement of a double-lumen tracheal tube is 
more likely to be successful if the bronchial part is inserted 
into the left main bronchus rather than the right.  
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 The bronchi are supplied by the bronchial arteries from the aorta, and 
drained by the azygos vein on the right and the hemiazygos vein on 
the left. There is also some drainage via the bronchial and pulmonary 
veins, which contributes to physiological shunt. Nerve supply is 
autonomic from the pulmonary plexus at the hilum. The 
parasympathetic supply vasodilates, bronchoconstricts, increases 
secretions and is responsible for sensation. The sympathetic supply 
vasoconstricts, bronchodilates via b2- receptors, and suppresses 
secretions via a-receptors.  
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ENDOTRACHEAL TUBE 
In 1926 anaesthesiologist author Guedel experimented with rubber 
tube item, including, dental dams, glows to construct the first 
endotracheal tube cuff. Guedel found that a supra glottic cuff position 
allowed gas to pass upward easily, It was found that, endotraceal cuff at 
the level of vocal cords could not be inflated properly, and hence placing 
the ETT cuff in the distal tracheal area could allow the secretions along 
the side of the tube 
After several experiments Guedel found that the proper positioning 
of the cuff would-be just below the vocal cord. 
Cuff system, design and materials:  
The American society for testing and materials (ASTM) specifies 
the requirements for the ideal design of endotracheal tube and cuff 5. As 
per the ASTM standard, the maximum distance from the tip of the 
endotrachel tube to end of the cuff, which varies with sizes of different 
tube size. End point of the cuff should not impinge the Murphy’s eye, and 
it should not herniate over the tube tip. It should be inflated 
symmetrically around the tube. 
The functions of cuff is to ensure the proper sealing of ETT 
between the patient trachea. The cuff should completely seal the trachea 
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and prevent the oropharyngeal secretions entering the trachea, and also to 
avoid the leakage of air around the tube. The cuff pressure should be such 
that, it would allow adequate perfusion of tracheal mucosa22. In sufficient 
inflation of cuff will result in entry of oropharyngeal secretion into the 
trachea and lungs leading to aspiration and many nosocomial pulmonary 
infections25,30. 
LOW AND HIGH PRESSURE CUFF: 
Intra cuff pressure: 
Cuff Pressure Cm H2O mmHg 
Ideal pressure 20-30 15-22 
High pressure >40 30 
Low pressure <20 18 
 
 
Cuff pressure monitor 
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Two types of cuff are available 
1. High pressure and low volume cuff 
2. High volume and low pressure cuff 
High pressure low volume tube (HPLV):  
In 1960, the endotracheal tube used were made of red rubber and 
was known as was high pressure low volume tube (HPLV). ETT used 
currently are made of Polyvinyl chloride (PVC) and polyurethane.  
HPLV required high intracuff pressure for covering the trachea and 
also to overcome the reduced compliance of the cuff. The cuff makes 
contact with small area of tracheal mucosa and renders it circular in 
shape. 
Disadvantages of HPLV tube: 
1. Prolonged contact with tracheal mucosa leads to ischemic 
necrosis of the tracheal mucosa. 
2. It may also inflate in a non-circular form and cause injury to 
the trachea. 
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Advantages of HPLV tube:  
1. Its reusability, 
2. Inexpensive, 
3. Lower incidence of sore throat, 
4. Better protection against aspiration, 
5. Since the cuff deflates and remains close to the ETT, they 
can easily visualise during intubation. 
High Volume low Pressure cuff (HVLP): 
In HVLP cuff has thin compliant wall that adapts to irregular 
contour of tracheal walls. 
Advantage: 
The intracuff pressure correlates closely to the tracheal mucosal 
pressure. 
Disadvantage: 
It can cause tracheal injury , if the cuff pressure is maintained on 
the steeper side of the pressure-volume- curve. 
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REVIEW OF LITERATURE 
 Malick et al20 (1996;77:731–4.) in their study had documented 35% 
reduction in analgesic requirement, when alkalised Lignocaine was 
used to inflate the ETT cuff.  
 Navarrro et al23, (1997, 9:394–97). in their study documented that, 
there was a reduction in the frequency of sore throat and 
hoarseness in the patients who received intracuff Lignocaine than 
the patients who were given intracuff air and saline at the time of 
discharge from PACU. 
 Haung et al 16(1998; 36:81-86.)in their study they concluded that 
buffering with or without warming but not just warming alone 
produced rapid diffusion from the cuffs. 
 Haung et al 15 (1999; 46:1: 82-86) had also determined the time 
interval at which minimum concentration of Lignocaine blocking 
the Rapidly Adapting Stretch Receptors (RAR) by diffusion across 
the cuff wall. It was determined that buffered Lignocaine exerted 
RAR blocking effect within 120-180 minutes after its 
administration8,9. 
 Sidou et al 26 (1999, 67:49-52). in their study, they compared the 
effects of Lignocaine, air, and saline and they have reported a 
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significant reduction in post-operative sore throat and cough in 
patients who were administered Lignocaine than the other patients.  
 Hirota et al 15 (2000;47:412–4). in their study they reported that 
inflation of the tracheostomy tube cuff with 4% Lignocaine 
remarkably reduced tube discomfort in patients who underwent 
tracheostomy following oral cancer resection. This was evaluated 
using visual analogue scale. 
 Dollo et al 6. (2001; 13:319-23) in their study they conducted in vitro 
study on diffusion of Lignocaine across the cuff and measured it 
using spectrometer. In his study Dolloett al used low volume, high 
pressureETT cuff with varying volumes of Lignocaine 2% (1-2ml) 
along with 8.4% of sodium bicarbonate (8-9ml). It was observed 
that 50% of Lignocaine diffused in 3 hours. 
 Estebe et al 7(2004: 92:361-66) in their study they used high volume 
low pressure ETT with fixed dose of 2ml of 2% Lignocaine with 
varying volumes of 8.4% sodium bicarbonate (8-15ml) in which 
the 50% Lignocaine was released in 5 hours. This was found to be 
lower than that of Dollo et al study. 
 Singh et al 28(2007;23: 163–7.) in their study they reported that the 
use of saline or 2% of Lignocaine without akalisation as liquid 
media for inflating ETT cuff decreased post-extubation reaction 
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 Jaichandran et al 31(2008; 52 (5); 536-540.) The study was to 
determine the optimal PH at which maximum diffusion of 
Lignocaine occurs across the ETT cuff. And they were concluded 
Lignocaine buffered at PH 7.4 as the optimal PH, for maximum 
diffusion across the ETT cuff and to block the cough receptors in 
the tracheal mucosa 
 Ahmed Sobhy,1 (2014 ; 451-455) did a study in 64 patients who 
required ventilator support for more than 48 hours. They 
documented that inflation of ETT cuff with Lignocaine reduced 
the requirement of propofol and Fentanyl by 30% than the control 
group 
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MATERIALS AND METHODOLOGY 
The study protocol was approved, before the commencement of the 
study by the Institutional Ethics Committee, Madras Medical College, 
RGGGH, Chennai. Informed consent was obtained from all the patients 
included in the study. 
Study Design & Duration: 
This study is a Prospective randomized control study for a duration 
of three months. 
Sample Size Calculation 
Sample size was determined based on  
Study: Intracuff alkalized lidocaine reduces sedative/ analgesic 
requirements for mechanically ventilated patients 
Authored by: Ahmed Sobhy Basuni  et al in Saudi Journal of Anesthesia 
Vol. 8, Issue 4, October-December 2014 
In this study there was a significant reduction (about 30%) in the 
requirements for propofol and Fentanyl inpatients who received intracuff 
alkalinized lidocaine; P < 0.001. 
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Description: 
• The confidence level is estimated at 95% 
• with a z value of 1.96 
• the confidence interval or margin of error is estimated at +/-15 
• Assuming that 80 percent of the sample will have the specified 
attribute p% =30 and q%=70 
n = p% x q% x [z/e%] ² 
n= 30 x 70 x [1.96/15]² 
n= 35.85 
Therefore 36 is the minimum sample size required for the study. 
In our study 50 subjects were chosen (n=25 in ETT Cuff + 
Alkalised Lignocaine Group and n=25 in ETT Cuff + Normal Saline 
Group) 
Study Population: 
Fifty patients were included in this study. Twenty five were 
intervention group and twenty five were control group. 
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Inclusion Criteria: 
1. Patients of age 18 years and above 
2. Patients with body mass index (BMI) ,< 35 kg/ m2were included 
in the study, 
3. American Society of Anaesthesiology physical status: I, II, III. 
4. Patients posted for both elective and emergency surgery were 
included. 
Exclusion Criteria: 
1. Post cardiac arrest patients, 
2. Patients with ventilation through tracheostomy, 
3. Pregnant women, 
4. History of seizures and other neurological deficit. 
Methodology: 
Patients were randomly assigned into two groups.  
 Group A (Intervention group)  
  Group B (Control group). 
  Fifty patients included in the study were segregated into two group 
with twenty five patients in each group. 
 Patients in group A (Intervention group) were administered 2% 
Lignocaine with 8.4% sodium bicarbonate (Alkalised Lignocaine) 
 42 
at a ratio of 1:1ml to inflate the ETT cuff before connecting to the 
ventilator to maintain a intra cuff pressure of 20-25mmHg 
  Patients in group B (Control group) were administered normal 
saline to inflate the ETT cuff who were also connected to the 
ventilator. 
  Endotracheal tube with 7-7.5 mm inner diameter were used for 
women and those with 7.5-8mm inner diameter were used for men. 
Both the group of patients were connected to ventilator on 
Synchronized Intermittent Mandatory ventilation (SIMV). The ventilator 
settings were adjusted to obtain a tidal volume of 6-8ml/kg and delivered 
with inspiratory flow rate of ≥60 l/min. Positive End Expiratory Pressure 
(PEEP) was fixed to maintain PaO2>90mmHg with FiO2 <0.6. 
Fentanyl infusion of 75µg/hr was given to the patients as post-
operative analgesic to maintain a score of <5 on the Behavioral Pain 
Scale (BPS). The level of analgesia was monitored hourly using 
Behavioral Pain Scale. 
If the score was ≥ 5, (outside the target level) the patients were 
administered Fentanyl bolus 25µg and were monitored. 
For each patient, in both the groups, the control (Group A) and 
intervention (Group B), the number of bolus dose of Fentanyl required for 
first 24 hours was recorded and this was compared between both the 
groups.  
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Behavioral Pain Scale (BPS):24 
Item Description Score 
Fascial Expression 
Relaxed 
Partially tightened (e.g., brow lowering) 
Fully tightened (e.g., eyelid closing) 
Grimacing 
1 
2 
3 
4 
Upper Limb 
movements 
No movements 
Partially bent 
Fully bent with finger flexion 
Permenently retracted 
1 
2 
3 
4 
Compliance with 
mechanical 
ventilation 
Tolerating movement 
Coughing but tolerating ventilation for 
most of the time 
Fighting ventilator 
Unable to control ventilation 
1 
2 
 
3 
4 
 
  
 44 
Behavioral Pain Scale (BPS):24 
Score Interpretation 
3 No pain 
12 Maximum pain 
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RESULTS 
This study is a prospective randomized control study conducted at 
the Institute of anaesthesiology and critical care, Madras Medical 
College, Chennai. The study population included fifty postoperative 
patient who required ventilator support. 
The patients were randomly assigned to two group. Group A 
(Intervention group) comprising of 25 patients ,received inracuff 
alkalized Lignocaine and Group B(Control group) comprising of 25 
patients received inracuff normal saline. 
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Age 
Distribution 
ETT Cuff + 
Alkalised Lignocaine Percentage 
ETT Cuff + 
Normal Saline Percentage 
≤ 20 years 2 8.00 1 4.00 
21-40 years 8 32.00 9 36.00 
41-60 years 14 56.00 14 56.00 
> 60 years 1 4.00 1 4.00 
Total 25 100 25 100 
 
Age Distribution ETT Cuff + Alkalised Lignocaine ETT Cuff + Normal Saline 
N 25 25 
Mean 44.88 45.32 
SD 13.39 12.52 
P value Unpaired t Test 0.9049 
 
Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the 41-60 years age class interval (n=14, 56%) with a mean 
age of 44.88 years. In the ETT Cuff + Normal Saline group patients, 
majority belonged to the same age class interval (n=14, 56%) with a 
mean age of 45.32 years. The association between the intervention groups 
and age distribution is considered to be not statistically significant since p 
> 0.05 as per unpaired t test.  
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Gender Distribution 
 
 
Gender 
Distribution 
ETT Cuff + 
Alkalised Lignocaine Percentage 
ETT Cuff + 
Normal Saline Percentage 
Male 12 48.00 12 48.00 
Female 13 52.00 13 52.00 
Total 25 100 25 100 
P value Fishers Exact Test 1.0000 
 
Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the female gender class interval (n=13, 52%). In the ETT 
Cuff + Normal Saline group patients, majority belonged to the same 
gender class interval (n=13, 52%). The association between the 
intervention groups and gender distribution is considered to be not 
statistically significant since p > 0.05 as per chi squared test  
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Height Distribution 
 
 
Height 
Distribution 
ETT Cuff + Alkalised 
Lignocaine Percentage 
ETT Cuff + 
Normal Saline Percentage 
≤ 140 cms 7 28.00 8 32.00 
141-150 cms 6 24.00 6 24.00 
151-160 cms 9 36.00 8 32.00 
161-170 cms 3 12.00 3 12.00 
Total 25 100 25 100 
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Height Distribution ETT Cuff + Alkalised Lignocaine 
ETT Cuff + Normal 
Saline 
N 25 25 
Mean 148.80 148.00 
SD 10.48 10.87 
P value Unpaired t Test 0.7922 
 
Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the 151-160 cms height class interval (n=9, 36%) with a 
mean height of 148.80 cms. In the ETT Cuff + Normal Saline group 
patients, majority belonged to the same height class interval (n=8, 32%) 
with a mean height of 148 cms. The association between the intervention 
groups and height distribution is considered to be not statistically 
significant since p > 0.05 as per unpaired t test. 
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Weight Distribution 
 
 
Weight 
Distribution 
ETT Cuff + 
Alkalised 
Lignocaine 
Percentage 
ETT Cuff + 
Normal 
Saline 
Percentage 
≤ 40 kgs 1 4.00 1 4.00 
41-50 kgs 6 24.00 6 24.00 
51-60 kgs 13 52.00 12 48.00 
61-70 kgs 5 20.00 6 24.00 
Total 25 100 25 100 
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Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the 51-60 kgs weight class interval (n=13, 52%) with a mean 
weight of 55.08 kgs. In the ETT Cuff + Normal Saline group patients, 
majority belonged to the same weight class interval (n=12, 48%) with a 
mean weight of 55.48 kgs. The association between the intervention 
groups and weight distribution is considered to be not statistically 
significant since p > 0.05 as per unpaired t test. 
Weight 
Distribution 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
N 25 25 
Mean 55.08 55.48 
SD 7.27 7.70 
P value Unpaired t Test 0.8511 
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BMI Distribution 
 
 
BMI Distribution 
ETT Cuff + 
Alkalised 
Lignocaine 
Percentage 
ETT Cuff 
+ Normal 
Saline 
Percentage 
Underweight (≤ 18.49) 0 0.00 0 0.00 
Normal (18.50 to 24.99) 11 44.00 10 40.00 
Overweight (25 to 29.99) 12 48.00 13 52.00 
Obese 2 8.00 2 8.00 
Total 25 100 25 100 
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BMI 
Distribution 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
N 25 25 
Mean 25.00 25.08 
SD 2.84 2.84 
P value Unpaired t Test 0.9212 
 
Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the overweight BMI class interval (n=12, 48%) with a mean 
BMI of 25.00. In the ETT Cuff + Normal Saline group patients, majority 
belonged to the same BMI class interval (n=13, 52%) with a mean BMI 
of 25.08. The association between the intervention groups and BMI 
distribution is considered to be not statistically significant since p > 0.05 
as per unpaired t test. 
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ASA Classification 
 
 
ASA 
Classification 
ETT Cuff + Alkalised 
Lignocaine 
Percent
age 
ETT Cuff + 
Normal Saline 
Percent
age 
ASA II 20 80.00 19 76.00 
ASA III 5 20.00 6 24.00 
Total 25 100 25 100 
P value Fishers Exact Test 0.7481 
 
Majority of the ETT Cuff + Alkalised Lignocaine group patients 
belonged to the ASA II class interval (n=20, 80%). In the ETT Cuff + 
Normal Saline group patients, majority belonged to the same ASA class 
interval (n=19, 76%). The association between the intervention groups 
and ASA classification is considered to be not statistically significant 
since p > 0.05 as per chi squared test  
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Heart Rate 
 
 
Heart 
Rate 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline P value Unpaired 
t Test N Mean SD N Mean SD 
0 hr 25 75.88 8.66 25 76.80 10.58 0.7381 
1 hr 25 73.40 7.08 25 78.92 9.54 0.0248 
2 hr 25 75.92 7.80 25 81.76 8.87 0.0171 
3 hr 25 77.36 8.18 25 82.44 9.12 0.0436 
4 hr 25 76.12 7.81 25 81.60 8.32 0.0203 
5 hr 25 75.44 8.32 25 80.72 7.76 0.0246 
6 hr 25 77.24 7.50 25 81.84 6.52 0.0250 
8 hr 25 75.88 7.93 25 80.52 7.93 0.0439 
10 hr 25 75.08 7.94 25 80.12 6.65 0.0189 
12 hr 25 75.16 6.86 25 79.64 6.67 0.0234 
16 hr 25 75.24 8.01 25 79.72 6.39 0.0340 
20 hr 25 74.84 6.71 25 80.12 7.53 0.0119 
24 hr 25 75.00 5.92 25 78.92 6.85 0.0354 
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In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean heart rate measurement was 75.76 bpm. In ETT Cuff + Normal 
Saline group, the mean heart rate measurement is 80.53 bpm. The 
decreased mean heart rate measurement in ETT Cuff + Alkalised 
Lignocaine group compared to the ETT Cuff + Normal Saline group is 
statistically significant as the p value is < 0.05 as per unpaired t- test 
indicating a true difference among study groups.  
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Systolic Blood Pressure 
 
 
Systolic 
Blood 
Pressure 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline P value 
Unpaired t Test N Mean SD N Mean SD 
0 hr 25 118.60 13.92 25 123.40 12.41 0.2044 
1 hr 25 119.08 12.70 25 123.44 12.65 0.2299 
2 hr 25 121.52 13.21 25 126.12 13.36 0.2269 
3 hr 25 124.16 11.96 25 127.48 11.26 0.3172 
4 hr 25 122.48 11.25 25 127.88 9.49 0.0530 
5 hr 25 124.20 9.70 25 121.52 24.73 0.6174 
6 hr 25 123.60 9.30 25 127.60 9.83 0.1459 
8 hr 25 123.16 9.91 25 125.84 10.55 0.3591 
10 hr 25 124.36 8.63 25 127.44 9.19 0.2278 
12 hr 25 124.12 9.20 25 124.92 9.47 0.7633 
16 hr 25 124.00 7.31 25 127.64 9.41 0.1336 
20 hr 25 123.92 7.99 25 128.40 8.44 0.0599 
24 hr 25 123.56 7.79 25 125.52 5.94 0.3226 
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In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean systolic blood pressure measurement was 123.18 mm Hg. In 
ETT Cuff + Normal Saline group, the mean systolic blood pressure 
measurement is 126.15 mm Hg. The increased mean systolic blood 
pressure measurement in ETT Cuff + Alkalised Lignocaine group 
compared to the ETT Cuff + Normal Saline group is statistically 
significant as the p value is < 0.05 as per unpaired t- test.  
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Diastolic Blood Pressure 
 
 
 
Diastolic Blood 
Pressure 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline P value 
Unpaired t Test N Mean SD N Mean SD 
0 hr 25 72.80 7.46 25 78.56 8.01 0.0114 
1 hr 25 73.96 6.12 25 80.20 7.62 0.0025 
2 hr 25 74.44 6.44 25 80.24 8.62 0.0099 
3 hr 25 76.12 6.13 25 83.12 7.89 0.0010 
4 hr 25 75.56 7.07 25 81.72 5.31 0.0011 
5 hr 25 76.12 7.30 25 80.88 5.64 0.0132 
6 hr 25 76.20 5.95 25 81.72 6.45 0.0028 
8 hr 25 74.68 6.85 25 81.12 5.33 0.0006 
10 hr 25 75.20 6.95 25 82.08 6.18 0.0006 
12 hr 25 75.48 7.95 25 79.32 6.12 0.0621 
16 hr 25 75.32 7.05 25 80.56 5.61 0.0056 
20 hr 25 75.04 7.01 25 83.00 5.28 0.0000 
24 hr 25 74.92 7.04 25 78.80 4.37 0.0242 
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In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean diastolic blood pressure measurement was 75.25 mm Hg. In 
ETT Cuff + Normal Saline group, the mean diastolic blood pressure 
measurement is 81.06 mm Hg. The decreased mean diastolic blood 
pressure measurement in ETT Cuff + Alkalised Lignocaine group 
compared to the ETT Cuff + Normal Saline group is statistically 
significant as the p value is < 0.05 as per unpaired t- test indicating a true 
difference among study groups.  
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Mean Arterial Pressure 
 
 
Mean 
Arterial 
Pressure 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
P value 
Unpaired t 
Test N Mean SD N Mean SD 
0 hr 25 102.92 11.62 25 93.40 8.75 0.0021 
1 hr 25 103.84 10.20 25 94.48 8.66 0.0010 
2 hr 25 89.92 8.24 25 95.52 9.45 0.0303 
3 hr 25 91.84 7.72 25 97.72 8.06 0.0113 
4 hr 25 91.00 8.21 25 96.92 5.70 0.0050 
5 hr 25 91.80 7.41 25 94.28 9.25 0.3011 
6 hr 25 91.68 6.30 25 96.76 5.66 0.0043 
8 hr 25 90.56 7.11 25 95.84 6.19 0.0074 
10 hr 25 91.40 6.72 25 97.00 6.03 0.0032 
12 hr 25 91.60 7.76 25 94.28 5.80 0.1734 
16 hr 25 91.44 6.21 25 96.04 5.46 0.0077 
20 hr 25 91.28 6.49 25 97.84 5.16 0.0003 
24 hr 25 90.96 6.05 25 94.08 3.03 0.0271 
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In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean arterial pressure measurement was 92.28 mm Hg. In ETT Cuff 
+ Normal Saline group, the mean arterial pressure measurement is 95.90 
mm Hg. The decreased mean arterial pressure measurement in ETT Cuff 
+ Alkalised Lignocaine group compared to the ETT Cuff + Normal 
Saline group is statistically significant as the p value is < 0.05 as per 
unpaired t- test indicating a true difference among study groups.  
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Behaviour Pain Scale 
 
 
Behaviour 
Pain Scale 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
P value 
Unpaired t 
Test N Mean SD N Mean SD 
0 hr 25 3.00 0.00 25 3.00 0.00 1.0000 
1 hr 25 3.00 0.00 25 3.36 0.49 0.0012 
2 hr 25 3.40 0.65 25 3.96 0.54 0.0017 
3 hr 25 3.64 0.64 25 4.40 0.82 0.0006 
4 hr 25 3.80 0.41 25 4.24 0.97 0.0445 
5 hr 25 4.24 0.72 25 3.84 0.85 0.0797 
6 hr 25 4.12 0.78 25 4.20 0.82 0.7249 
8 hr 25 3.72 0.84 25 3.80 0.76 0.7266 
10 hr 25 3.88 0.93 25 4.40 0.96 0.0570 
12 hr 25 3.80 1.08 25 3.80 0.91 1.0000 
16 hr 25 3.84 1.03 25 4.40 1.00 0.0567 
20 hr 25 3.64 0.64 25 4.28 0.89 0.0055 
24 hr 25 3.76 0.44 25 3.84 0.37 0.4897 
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In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean behaviour pain scale measurement was 3.46 points. In ETT 
Cuff + Normal Saline group, the mean behaviour pain scale measurement 
is 3.99 points. The decreased mean behaviour pain scale measurement in 
ETT Cuff + Alkalised Lignocaine group compared to the ETT Cuff + 
Normal Saline group is statistically significant between 1-4 hours, 10th 
hours and 16 to 20hrs as the p value is < 0.05 as per unpaired t- test 
indicating a true difference among study groups.  
  
 65 
Total Fentanyl Dose 
 
 
Total Fentanyl 
Dose 
ETT Cuff + Alkalised 
Lignocaine Percentage 
ETT Cuff + 
Normal Saline Percentage 
25 micrograms 15 60.00 2 8.00 
50 micrograms 5 20.00 5 20.00 
75 micrograms 5 20.00 13 52.00 
100 micrograms 0 0.00 5 20.00 
Total 25 100 25 100 
 
  
15
5 5
0
2
5
13
5
0
2
4
6
8
10
12
14
16
25 micrograms 50 micrograms 75 micrograms 100 micrograms
N
um
be
r o
f P
at
ie
nt
s
Total Fentanyl Dose
ETT Cuff + Alkalised lignocaine ETT Cuff + Normal Saline
 66 
Total Fentanyl 
Dose 
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
N 25 25 
Mean 40.00 71.00 
SD 20.41 21.26 
P value Unpaired t Test 0.0000 
 
In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean total Fentanyl dose was 40 micrograms. In ETT Cuff + Normal 
Saline group, the mean total Fentanyl dose is 71 micrograms. The 
decreased mean total Fentanyl dose in ETT Cuff + Alkalised Lignocaine 
group compared to the ETT Cuff + Normal Saline group is statistically 
significant as the p value is < 0.05 as per unpaired t- test indicating a true 
difference among study groups.  
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Cough Incident 
 
 
Cough 
Incident 
ETT Cuff + 
Alkalised 
Lignocaine 
Percentage ETT Cuff + Normal Saline Percentage 
≤ 3 times 16 64.00 2 8.00 
4-5 times 7 28.00 14 56.00 
6-7 times 2 8.00 9 36.00 
Total 25 100 25 100 
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Cough Incident ETT Cuff + Alkalised Lignocaine ETT Cuff + Normal Saline 
N 25 25 
Mean 3.32 5.04 
SD 1.22 1.31 
P value Unpaired t Test 0.0000 
 
In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean cough incident measurement was 3.32 times. In ETT Cuff + 
Normal Saline group, the mean cough incident measurement is 5.04 
times. The decreased mean cough incident measurement in ETT Cuff + 
Alkalised Lignocaine group compared to the ETT Cuff + Normal Saline 
group is statistically significant as the p value is < 0.05 as per unpaired t- 
test indicating a true difference among study groups.  
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Ineffective Trigger  
 
 
Ineffective 
Trigger 
ETT Cuff + 
Alkalised 
Lignocaine 
Percentage ETT Cuff + Normal Saline Percentage 
≤ 3 times 17 68.00 4 16.00 
4-5 times 7 28.00 12 48.00 
6-7 times 1 4.00 9 36.00 
Total 25 100 25  100 
  
17
7
1
4
12
9
0
2
4
6
8
10
12
14
16
18
≤ 3 times 4-5 times 6-7 times
N
um
be
r 
of
 P
at
ie
nt
s
Ineffective Trigger
ETT Cuff + Alkalised lignocaine ETT Cuff + Normal Saline
 70 
Ineffective 
Trigger  
ETT Cuff + Alkalised 
Lignocaine 
ETT Cuff + Normal 
Saline 
N 25 25 
Mean 3.12 4.96 
SD 1.30 1.34 
P value Unpaired t Test 0.0000 
 
In patients belonging to ETT Cuff + Alkalised Lignocaine group, 
the mean ineffective trigger measurement was 3.12 times. In ETT Cuff + 
Normal Saline group, the mean ineffective trigger measurement is 4.96 
times. The decreased mean ineffective trigger measurement in ETT Cuff 
+ Alkalised Lignocaine group compared to the ETT Cuff + Normal 
Saline group is statistically significant as the p value is < 0.05 as per 
unpaired t- test indicating a true difference among study groups.  
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DISCUSSION 
This study is a prospective randomized control study conducted at 
the Institute of Anesthesiology and critical care, Madras Medical College, 
Chennai. 
The study populations included fifty (n=50) postoperative patients 
who required ventilator support. The patients were randomly segregated 
into two groups. 
Group A (Intervention group - n=25 patients) were administered 
intracuff alkalized Lignocaine 
Group B (Control group – n=25 patients) were administered 
intracuff Normal Saline. 
All the 50 (n=50) patients were given intra venous Fentanyl 
infusion in the dose of 75µgs/hour to achieve a score below 5. The levels 
of analgesia was monitored hourly for 24 hours using behavioral pain 
scale (BPS) . If the BPS score was ≥ 5, the patients were administered 
Fentanyl 25µg as as a bolus dose. The total bolus dose of Fentanyl 
required for 24 hours in each group was calculated. 
The mean heart rate measurement was meaningfully less in ETT 
Cuff + Alkalised Lignocaine group compared to the ETT Cuff + Normal 
Saline group by 4.97 bpm. This significant difference of 6% decrease in 
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mean heart rate measurement in ETT Cuff + Alkalised Lignocaine group 
compared to the ETT Cuff + Normal Saline group is true and has not 
occurred by chance.  
In this study mean heart rate measurement was significantly and 
consistently lower in ETT Cuff + Alkalised Lignocaine group compared 
to the ETT Cuff + Normal Saline group.  
The mean diastolic blood pressure measurement was meaningfully 
less in ETT Cuff + Alkalised Lignocaine group compared to the ETT 
Cuff + Normal Saline group by 5.81 mm Hg. This significant difference 
of 7% decrease in mean diastolic blood pressure measurement in ETT 
Cuff + Alkalised Lignocaine group compared to the ETT Cuff + Normal 
Saline group is true and has not occurred by chance. In this study mean 
diastolic blood pressure measurement was consistently lower in ETT Cuff 
+ Alkalised Lignocaine group compared to the ETT Cuff + Normal 
Saline group. 
The mean arterial pressure measurement was meaningfully less in 
ETT Cuff + Alkalised Lignocaine group compared to the ETT Cuff + 
Normal Saline group by 3.62 mm Hg. This significant difference of 4% 
decrease in mean arterial pressure measurement in ETT Cuff + Alkalised 
Lignocaine group compared to the ETT Cuff + Normal Saline group is 
true and has not occurred by chance. In this study mean arterial pressure 
 73 
measurement was significantly lower in ETT Cuff + Alkalised 
Lignocaine group compared to the ETT Cuff + Normal Saline group.  
The mean behaviour pain scale measurement was meaningfully 
less in ETT Cuff + Alkalised Lignocaine group compared to the ETT 
Cuff + Normal Saline group by 0.53 points. This significant difference of 
13% decrease in mean behaviour pain scale measurement in ETT Cuff + 
Alkalised Lignocaine group compared to the ETT Cuff + Normal Saline 
group is true and has not occurred by chance. In this study mean 
behaviour pain scale measurement was significantly and consistently 
lower in ETT Cuff + Alkalised Lignocaine group compared to the ETT 
Cuff + Normal Saline group.  
The mean total Fentanyl dose was remarkably less in ETT Cuff + 
Alkalised Lignocaine group compared to the ETT Cuff + Normal Saline 
group by 31 micrograms. This significant difference of 40% decrease in 
mean total Fentanyl dose in ETT Cuff + Alkalised Lignocaine group 
compared to the ETT Cuff + Normal Saline group is true and has not 
occurred by chance.  
In this study mean total Fentanyl dose was significantly lower in 
ETT Cuff + Alkalised Lignocaine group compared to the ETT Cuff + 
Normal Saline group.  
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Out of the 25 patients (n=25) in the Group A (Intervention group) 
15 patients required 25µg of Fentanyl, 5 patients required 50µg and 
another 5 patients required 75µg of Fentanyl. 
In the Group B (n=25) (Control group) 2 patients required 25µg of 
Fentanyl, 5 patients needed 50µg of Fentanyl and 13 required 75µg and 5 
were given 100 µg of Fentanyl. 
This study had documented 40% reduction in the Fentayl 
requirement during the first 24 hours in patients with intracuff alkalized 
Lignocaine . 
Malik et al has reported 35% reduction in Fentanyl requirement in 
patients with intracuff alkalized Lignocaine20. Ahmed Sobhy had also 
documented 30% reduction in Fentanyl and propofol requirement in 
patients with intracuff Lignocaine1. 
The results of this study were comparable to the results of above 
quoted studies. 
In this study 2% Lignocaine and 8.4% of sodium bicarbonate was 
used in the rartio of 1:1ml. Various studies have shown that variation in 
the concentration of sodium bicarbonate injected into the cuff had no 
effect on the diffusion of Lignocaine. 
Lignocaine is known to be absorbed rapidly from tracheo brocheal 
mucosa. However for systemic Lignocaine to be effective in reduceing 
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ETT discomfort a very high plasma concentration of Lignocaine is 
required (IV Lignocaine 2mg/kg give plasma Lignocaine level >3µg/ml). 
than that attained in case of Lignocaine diffusion with 8.4% sodium 
bicorbanate(<0.08µg/ml) suggesting that improved ETT tolerance after 
intracuff alkalized Lignocaine is local rather than a systemic effect. 
The present study had also documented significant reduction in the 
incidence of cough and restlessness in the the intervention group than the 
control group. 
In the present study, the frequency of ineffective trigger was found 
to be lower in patients who received intracuff alkalized Lignocaine than 
the control group. This is attributed to the increased ETT tolerance and 
patient comfort associated with intracuff alkalized Lignocaine. 
Ineffective trigger occurs when patients effort fails to reduce 
airway pressure below ventilator trigger sensitivity. However ineffective 
trigger occurs particularly due to improper ventilator settings 
(inappropriate trigger sensitivity) or abnormal pulmonary mechanics 2,3,4. 
Also sedatives and analgesics have shown to depress the inspiratory drive 
and decreases the inspiratory muscle effort and thereby increasing 
ineffective trigger12,33. 
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Sign et al had reported that use of saline or 2 % Lignocaine without 
alkalization as liquid media for inflating ETT cuff reduced post- 
extubation reaction28.  
In case of cuff rupture Lignocaine and sodium bicarbonate mixture 
could be irritative. However in vitro and vivo study showed no cuff 
obstruction or rupture. Similarly this study had no events of cuff rupture 
or obstruction,9,27,34. 
Some incidents of cuff rupture have been reported when 
Lignocaine was used as lubricant or for local anaesthesia35. 
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SUMMARY 
 This study is a prospective randomized control study conducted at 
the Institute of Anaesthesiology and critical care, Madras Medical 
College, Chennai. 
 Study population included fifty post operative patients assigned into 
two groups (A and B)  
 Group A (Intervention group ) were administered intracuff alkalized 
Lignocaine 
 Group B (Control group ) were administered intracuff normal saline 
 Fentanyl IV infusion in a dose of 75 µg was administered to all the 
fifty patients to achive a BPS of < 5. The effect of analgesia was 
monitored using Behavioural Pain Scale (BPS)24 . 
 Whenever the score was ≥ 5, patients were administered Fentanyl 
25 µg IV as a bolus dose. 
 The mean heart rate measurement in ETT Cuff + Alkalised 
Lignocaine group is less when compared to the ETT Cuff + Normal 
Saline group, which is statistically significant. 
 The mean systolic blood pressure measurement in ETT Cuff + 
Alkalised Lignocaine group is less when compared to the ETT Cuff 
+ Normal Saline group, which is statistically significant 
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 The mean diastolic blood pressure measurement in ETT Cuff + 
Alkalised Lignocaine group is less when compared to the ETT Cuff 
+ Normal Saline group, which is statistically significant 
 The mean arterial pressure measurement in ETT Cuff + Alkalised 
Lignocaine group is less when compared to the ETT Cuff + Normal 
Saline group, which is statistically significant. 
 The mean behaviour pain scale measurement in ETT Cuff + 
Alkalised Lignocaine group is less when compared to the ETT Cuff 
+ Normal Saline group, which is statistically significant. 
 The mean total Fentanyl dose in ETT Cuff + Alkalised Lignocaine 
group is less when compared to the ETT Cuff + Normal Saline 
group, which is statistically significant 
 The mean cough incident measurement in ETT Cuff + Alkalised 
Lignocaine group is less when compared to the ETT Cuff + Normal 
Saline group which is statistically significant 
 The mean ineffective trigger measurement in ETT Cuff + Alkalised 
Lignocaine group is less when compared to the ETT Cuff + Normal 
Saline group which is statistically significant 
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CONCLUSION 
From this study, It is conclude that the use of intracuff alkalized 
Lignocaine results in a significant decrease in the sedative/ analgesic 
requirement and frequency of ineffective trigger when compared to the 
use of intracuff saline and hence have better ET tube tolerance and 
improves patients compliance.  
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PROFORMA 
DATE:      ROLL NO:    
 
NAME:  
 
AGE:      SEX:     IP NO: 
 
DIAGNOSIS: 
 
SURGICAL PROCEDURE DONE: 
 
Ht:          CVS:    
 
Wt:          RS: 
 
AIRWAY:  MMS -       IID -   - 
 
PRE OP ASSESSMENT: 
 
HISTORY: Any Co-morbid illness 
 H/O Documented Difficult Airway 
 H/O previous surgeries 
 
INTRAOP EVENTS: 
 
MEASURES OF STUDY OUTCOME: 
GROUP A (INTRACUFF WITH ALKALIZED LIGNOCAINE) 
FENTANYL INFUSION 100µg/hr 
 1hr 2hr 3hr 4hr 5hr 6hr 8hr 10hr 12hr 16hr 20hr 24h 
 HR:              
SBP:             
DBP:             
MAP:             
BPS:             
COUGH INCIDENCE: 
INEFFECTIVE TRIGGER: 
 TOTAL FENTANYL 
  
 GROUP B ( INTRACUFF WITH NORMAL SALINE) 
FENTANYL INFUSION 100µg/hr :  
 1hr 2hr 3hr 4hr 5hr 6hr 8hr 10hr 12hr 16hr 20hr 24h 
 HR:              
SBP:             
DBP:             
MAP:             
BPS:             
COUGH INCIDENCE: 
INEFFECTIVE TRIGGER: 
 TOTAL FENTANYL  
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INFORMATION TO PARTICIPENTS 
Investigator: Dr SARAVANAN K 
Name of the Participant: 
Title: “A STUDY ON INTRACUFF ALKALIZED LIGNOCAINE REDUCES 
ANALGESIC/SEDATIVE REQUIREMENT FOR MECHANICALLY 
VENTILATED PATIENTS IN A TERTIARY CARE HOSPITAL” 
You are invited to take part in this research study. We have got approval from 
the IEC. Your are asked to participate because you satisfy the eligibility criteria. We 
want to compare and study the safety and efficacy of Intracuff alkalized Lignocaine 
reduces analgesic/sedative requirement for mechanically ventilated patients 
What is the Purpose of the Research: 
2. To know its consequence on patient – ventilator interaction 
The Study Design: 
All the patients in the study will be divided into two groups. 
Group A – ETT cuff inflated with alkalized Lignocaine  
Group B - ETT cuff inflated with normal saline  
In mechanically ventilated patient 
Benefits 
ETT tolerance and reduses the requirements of analgesic/sedatives. 
This intervention has been shown to be well tolerated as shown by previous 
studies.And if you do not want to participate you will have alternative of setting the 
standard treatment and your safety is our prime concern. 
Time : 
Date : 
Place : 
Signature / Thumb Impression of Patient 
Patient Name: 
Signature of the Investigator : ____________________________ 
Name of the Investigator : ____________________________  
1. To investigate the effect of intracuff alkalized Lignocaine on 
sedative/analgesic requirements for mechanically ventilated patients. 
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PATIENT CONSENT FORM 
Study Title: “A PROSPECTIVE RANDOMIZED STUDY ON INTRACUFF 
ALKALIZED LIGNOCAINE REDUCES 
ANALGESIC/SEDATIVE REQUIREMENT FOR 
MECHANICALLY VENTILATED PATIENTS IN A 
TERTIARY CARE HOSPITAL” 
 
Study Center: INSTITUTE OF ANAESTHESIOLOGY AND CRITICAL CARE 
RAJIV GANDHI GOVT. GENERAL HOSPITAL, MADRAS 
MEDICAL COLLEGE,  CHENNAI-0 3. 
 
Participant name: Age: Sex: I.P.No: 
 
I confirm that I have understood the purpose of procedure for the above study. 
I have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. 
 
I have been explained about the pitfall in the procedure. I have been explained 
about the safety,advantage and disadvantage of the technique. 
 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at anytime without giving any reason. 
 
I understand that investigator, regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study. I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from the study. 
 
Time:  
 
Date: Signature / thumb impression of patient  
 
Place: Patient name: 
 
Signature of the investigator: 
 
Name of the investigator: 
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S.NO NAME AGE SEX IP.NO DIAGNOSIS SURGERY HT WT BMI ASA 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1hr 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR
1 govindammal 57 F 76793 ca mandible hemi mandibulectomy 135 60 32 lll 85 88 86 85 90 83 79 84 88 74 76 74 75 122 121 126 128 130 126 124 126 136 126 129 125 123
2 sengammal 40 F 79338 ca OG junction total gastrectomy 140 48 24 II 65 73 74 79 73 76 79 74 80 73 75 76 78 116 115 113 119 123 125 126 121 120 138 121 125 126
3 rajakumar 50 M 74175 ca tongue hemi glossectomy 135 45 25 lll 88 88 83 85 88 94 75 76 79 78 75 76 77 126 126 121 126 130 126 120 119 134 126 126 129 126
4 Anbalagan 46 M 74593 cholilithiasis cholecystectomy 160 62 24 II 65 68 74 72 76 74 80 72 79 72 75 74 76 109 106 118 113 105 126 126 115 116 109 113 126 126
5 Murugan 67 M 69175 chronic calcified pancriatitis frey's procedure 165 68 25 II 92 90 88 92 102 92 88 87 84 85 83 86 88 116 115 116 113 126 129 115 113 124 112 109 124 121
6 Nirmala 51 F 73558 fibroadenoma left breast excision 145 50 24 II 74 73 76 78 84 82 86 89 80 81 90 84 82 123 125 129 126 129 116 120 124 126 122 130 126 121
7 Rajakumari 32 F 64422 odantogenic myxoma excision 130 45 26 II 92 95 90 105 88 86 82 83 84 88 89 94 86 132 134 130 140 131 136 126 121 129 134 126 121 126
8 jayaraman 25 M 64488 lumbar scoliosis deformity correction 158 50 20 II 72 74 79 85 80 78 76 72 80 71 76 70 73 116 115 118 126 124 129 116 113 120 116 126 116 115
9 Nithya 20 F 71914 maxillary retroganthism B/L sagittal split osteotomy 155 54 22 II 74 72 76 82 72 70 79 78 84 82 80 86 80 123 124 124 129 125 126 121 126 130 124 128 132 126
10 Devika 15 F 69923 fracture  Rt mandible ORIF 145 44 21 II 64 70 72 78 90 88 80 85 86 89 78 78 74 116 115 113 116 126 126 121 126 130 124 128 132 126
11 Remesh 45 M 64589 stricture esophagus coloplasty 167 68 24 II 96 99 98 94 90 91 94 88 86 86 92 90 88 98 99 100 110 94 98 102 96 99 101 112 106 105
12 Sriniasan 60 M 66714 ca r buccal mucosa WLE and manibulectomy 158 58 23 lll 77 74 75 75 80 73 88 78 75 77 70 75 71 101 103 106 105 109 110 115 109 109 126 119 112 115
13 Gopalan 55 M 68189 periampulary ca whipples procedure 156 60 25 III 66 68 64 70 75 71 74 75 78 80 87 84 85 126 122 134 138 130 126 124 134 121 129 130 136 135
14 Sujatha 32 F 62689 lefort 2 fracture ORIF 155 54 22 II 66 69 68 70 68 77 69 66 70 74 78 71 74 99 102 105 113 104 115 103 115 120 119 112 116 126
15 kannan 38 M 54568 fracture  Rt mandible ORIF 145 52 25 II 88 84 90 82 86 89 84 88 92 82 81 86 80 138 134 140 139 136 135 130 135 134 139 136 129 130
16 Meenakkshi 52 F 74891 periampulary ca whipples procedure 138 58 30 II 65 66 68 72 74 76 79 88 78 86 82 90 82 141 145 146 138 134 141 138 139 130 139 136 140 143
17 Kumarevel 58 M 74886 ca buccal mucosa WLE and manibulectomy 162 66 25 II 74 72 76 88 70 72 78 71 74 86 72 71 74 102 113 114 124 120 115 126 121 124 129 120 121 123
18 Krishnamoorthy 56 M 54362 chronic calcified pancriatitis frey's procedure 158 66 26 II 88 84 86 89 90 92 96 96 90 84 82 85 80 109 103 104 103 110 115 120 125 121 121 119 118 113
19 Rani 40 F 67115 incisional hernia mesh repair 145 62 29 II 74 76 79 84 78 76 79 74 88 89 82 80 84 132 124 129 130 126 121 129 126 131 136 134 126 123
20 Megala 35 F 78112 ca tongue hemi glossectomy 152 58 25 II 75 74 76 80 78 74 76 78 70 71 73 79 70 141 142 144 146 139 136 139 136 129 124 128 132 134
21 kannayan 36 M 82115 ca nasal cavity WLE and sentinal nodal biopsy 142 52 26 lll 88 84 90 82 86 85 88 89 78 74 76 80 78 124 129 130 129 126 130 134 136 129 122 125 129 121
22 Saroja 48 F 58188 ca maxilla maxillectomy and ffp 142 58 29 lll 66 64 68 88 89 90 92 88 80 84 89 80 81 94 99 102 105 108 112 126 120 119 126 124 113 115
23 Kalaivani 46 F 66713 fracture  left mandible ORIF 146 54 25 II 88 90 92 99 84 83 86 88 82 85 84 88 88 130 125 124 136 121 124 121 129 134 121 119 115 118
24 govindhan 60 M 74183 odantogenic myxoma excision 136 40 22 II 64 62 70 68 78 74 79 68 64 65 68 62 60 129 126 139 126 132 134 139 134 129 124 126 124 123
25 Maheswari 58 F 78164 fibroadenoma left breast excision 140 55 28 II 74 76 75 79 71 72 80 78 74 75 80 84 89 102 115 113 126 124 128 129 120 115 116 124 125 129
Group A:ETT CUFF FILLED WITH ALKALIZED LOGNOCAINE
HEART RATE SYSTOLIC BLOOD PRESSURE
  
 
0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR T0TAL FENTANYL COUGH INCIDENT INEFFECTIVE TRIGGER
74 70 74 80 90 70 84 74 88 74 74 70 84 106 104 90 96 104 88 97 90 104 92 92 88 97 3 3 3 3 4 4 4 4 5 3 4 4 4 25 3 3
65 64 69 68 74 72 78 74 72 84 68 69 70 99 98 84 85 90 89 94 89 88 102 86 88 88 3 3 3 3 4 4 4 4 4 6 3 4 4 25 4 3
74 71 74 78 89 74 76 78 64 82 74 71 79 108 107 90 94 102 90 90 90 87 96 91 90 95 3 3 3 3 4 4 4 4 5 3 3 3 4 25 3 4
68 69 70 74 69 68 79 64 68 63 69 69 70 93 93 86 87 81 87 94 81 84 78 84 88 88 3 3 4 4 4 4 5 3 3 3 4 5 3 50 2 3
72 76 68 70 72 84 72 74 80 78 74 84 70 100 102 84 84 90 99 86 87 95 90 86 97 87 3 3 3 3 3 4 4 4 5 3 4 5 3 50 2 3
70 74 72 74 84 82 79 74 70 76 88 80 74 105 108 91 90 99 93 92 90 86 91 102 96 90 3 3 3 3 4 4 4 4 4 4 5 3 4 25 3 2
82 85 80 89 81 84 79 79 80 88 82 80 86 115 117 96 106 98 101 94 93 96 103 96 94 99 3 3 3 4 4 6 3 3 4 5 3 4 4 50 4 3
68 69 70 72 70 74 68 69 76 69 64 69 64 100 100 86 90 88 92 84 83 90 84 85 85 81 3 3 3 4 4 5 3 3 6 3 5 3 4 75 5 4
69 68 69 74 72 70 69 68 70 62 68 72 70 105 105 87 92 90 88 86 87 90 82 88 92 88 3 3 3 4 4 4 4 4 5 3 3 4 4 25 3 2
69 70 71 74 76 80 74 75 73 74 69 68 64 100 100 85 88 92 95 90 92 92 90 88 89 85 3 3 3 4 4 6 3 3 4 5 3 3 3 50 4 3
64 69 68 70 63 65 70 70 69 64 68 63 70 86 89 78 82 72 76 80 78 79 76 82 77 82 3 3 3 4 4 4 5 3 3 3 4 4 4 25 3 2
69 70 69 68 72 69 70 68 69 76 70 71 69 90 92 81 80 84 82 85 82 82 92 86 85 84 3 3 3 3 3 3 4 4 4 6 4 4 4 25 2 1
74 78 82 80 84 86 80 89 82 84 80 88 80 108 108 99 99 99 99 95 104 95 99 97 104 98 3 3 3 3 4 4 4 6 3 3 3 4 4 25 3 2
64 72 74 78 69 75 69 68 70 72 76 70 71 87 92 84 89 80 88 80 84 86 88 88 85 89 3 3 3 4 4 5 4 4 5 3 3 3 4 50 2 3
84 80 79 85 74 76 82 80 81 79 88 80 81 120 116 99 103 95 96 98 98 99 99 104 96 97 3 3 4 4 4 5 3 3 3 4 4 4 4 25 2 2
88 84 85 89 80 90 86 85 88 90 80 86 80 123 124 105 105 98 107 103 103 102 106 98 104 101 3 3 3 3 4 5 3 3 4 6 3 3 4 25 3 2
69 70 74 78 72 74 79 72 76 78 70 72 80 91 98 87 94 88 88 95 88 92 95 86 88 94 3 3 4 5 3 4 6 3 3 5 3 3 4 75 4 5
64 68 62 69 64 63 70 72 71 70 75 70 76 94 90 76 80 79 80 86 90 88 87 90 86 88 3 3 3 4 4 4 4 5 3 3 3 4 4 25 2 4
84 82 79 76 80 81 78 84 80 82 83 84 86 116 110 96 94 95 94 95 98 97 100 100 98 98 3 3 3 4 4 4 4 5 3 3 4 4 4 25 3 2
84 85 89 86 83 88 90 84 82 86 89 84 80 122 123 107 106 102 104 106 101 98 99 102 100 98 3 3 5 3 3 4 5 3 3 4 6 3 3 75 6 5
74 78 76 70 73 78 70 79 72 69 75 70 76 107 112 94 90 90 95 90 98 91 86 92 90 91 3 3 4 4 4 4 4 5 3 3 3 4 4 25 3 2
63 68 70 74 68 69 74 63 68 64 70 69 63 83 88 80 84 80 83 90 82 85 85 88 83 80 3 3 4 5 3 3 5 3 4 4 6 3 3 75 5 6
84 80 85 79 74 80 81 83 88 80 82 84 86 114 110 98 98 90 94 94 98 103 94 94 94 96 3 3 3 3 4 4 4 4 5 3 3 3 3 25 2 2
74 78 79 74 78 81 70 69 74 72 77 76 74 110 110 99 90 96 98 93 90 92 90 93 92 90 3 3 5 3 4 4 5 3 3 4 6 3 4 75 6 5
70 71 73 74 78 70 78 72 69 71 70 77 70 91 100 86 90 93 89 95 88 84 86 88 93 90 3 3 4 4 4 4 5 3 3 3 4 4 4 25 4 5
                                          DIASTOLIC BLOOD PRESSURE MEAN ARTERIAL PRESSURE                               BEHAVIOUR PAIN SCALE
  
 
S.NO NAME AGE SEX IP.NO DIAGNOSIS SURGERY HT WT BMI ASA 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1hr 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR
1 ramkumar 45 M 64581 fracture  left mandible ORIF 167 68 24 II 84 82 86 88 90 82 86 86 90 84 89 90 84 126 121 121 128 134 126 124 129 130 128 126 130 120
2 Sriniasan 60 M 66754 ca buccal mucosa WLE and manibulectomy 158 58 23 III 76 74 73 80 83 75 76 78 74 76 82 79 72 102 105 110 112 110 116 115 113 116 119 130 119 116
3 gopinath 55 M 66881 ca ilio caecal junction laprotoy 156 60 25 II 68 69 70 76 64 68 73 69 65 68 77 70 74 132 130 131 138 129 126 134 129 132 130 136 126 122
4 sujitha 32 F 62555 odantogenic myxoma excision 155 54 22 II 82 86 82 88 79 80 81 88 79 72 76 79 70 126 129 123 130 126 135 136 134 129 126 130 134 130
5 mariyadass 38 M 54824 # LT maxilla ORIF 145 52 25 II 72 73 72 70 73 76 80 75 70 72 76 72 70 119 116 115 120 121 126 128 120 125 126 120 126 129
6 manimegalai 57 F 76333 ca mandible hemi mandibulectomy 135 60 32 II 64 65 67 67 78 63 68 69 73 69 74 86 70 129 138 139 136 140 13 136 135 142 136 132 139 132
7 raammayi 40 F 79653 ca OG junction total gastrectomy 140 48 24 III 74 76 78 84 72 71 78 70 73 77 85 72 73 102 105 116 130 115 116 124 108 109 105 126 122 124
8 mahendiran 50 M 74135 ca tongue hemi glossectomy 135 45 25 III 94 92 98 96 102 86 89 89 94 82 88 90 84 126 121 126 123 130 120 121 136 138 130 139 136 130
9 rajamurali 46 M 74445 cholilithiasis cholecystectomy 160 62 24 II 88 90 94 86 93 80 84 88 98 85 83 90 82 116 126 129 116 130 126 114 115 130 115 116 130 126
10 perumal 67 M 69452 peri ampulary ca whipples procedure 165 68 25 III 76 78 74 82 77 70 78 86 70 72 89 80 86 132 130 131 140 142 138 131 140 120 121 130 131 134
11 meena 52 F 65248 chondrosarcoma rt manidible WLE and manibulectomy 138 58 30 II 67 74 78 69 69 65 73 69 78 74 80 75 82 135 130 138 126 129 126 130 132 139 126 139 124 121
12 kulandaivel 58 M 74886 ccpancriatitis freys procedure 162 66 25 II 88 89 88 92 84 83 92 86 88 95 84 86 86 126 121 128 134 126 129 134 121 126 130 126 119 124
13 krishnan 56 M 56542 poly trauma ORIF RT rt UL and femour n tibia 158 66 26 II 77 76 79 80 89 74 78 78 83 70 75 70 73 99 98 102 105 126 120 121 119 130 115 128 129 130
14 meriyamma 40 F 65252 incisional hernia mesh repair 145 62 29 II 66 68 67 70 71 78 69 64 68 64 61 69 68 130 131 136 126 129 134 138 132 130 140 125 130 126
15 sangeetha 35 F 74542 fracture  Rt mandible ORIF 152 58 25 II 88 89 94 82 86 90 81 88 76 72 78 84 70 129 130 131 134 119 118 129 130 129 120 121 136 120
16 karuppannan 36 M 80981 ca stomach partial gastrectomy 142 52 26 III 93 89 88 91 94 102 90 88 92 86 84 87 87 142 140 148 132 126 134 120 130 126 126 121 140 125
17 Saroja 48 F 65821 lefort 1 fracture ORIF 142 58 29 II 80 86 86 90 84 83 89 80 88 80 79 86 84 133 130 126 130 129 121 138 116 124 115 116 120 121
18 lakshmi 46 F 66969 lumbar disc disease posterir stabilisation 146 54 25 II 76 74 78 79 86 72 74 82 83 88 90 86 82 139 135 140 138 140 131 140 139 132 126 140 138 130
19 govindhan 60 M 85647 # lt ramus of mandible ORIF 136 40 22 II 70 72 74 76 73 85 73 74 88 74 70 79 72 115 116 115 118 126 129 130 131 136 129 126 130 116
20 meenammal 58 F 88585 cholelithiasis lap and open cholecystectomy 140 55 28 II 69 68 70 88 74 76 80 72 71 76 89 82 84 128 121 129 130 136 131 135 128 124 130 135 128 130
21 neelamegam 51 F 79658 ca OG junction total gastrectomy 145 50 24 II 80 86 84 82 88 82 89 88 96 82 86 84 82 119 115 120 121 126 120 116 115 129 117 126 109 126
22 Rajakumari 32 F 56541 fracture  left mandible ORIF 130 45 26 II 70 74 76 79 80 81 85 86 81 89 89 84 82 130 145 149 150 142 139 140 139 140 142 146 139 136
23 jayaraman 25 M 25653 peri ampulary ca whipples procedure 158 50 20 III 80 78 79 80 85 76 74 78 79 85 78 72 70 98 99 94 102 105 96 99 98 102 105 100 110 112
24 Nithya 20 F 71546 stricture esophagus coloplasty 155 54 22 II 70 74 78 80 72 73 84 79 70 79 72 80 75 116 115 116 126 121 120 125 128 120 130 131 136 128
25 devikala 26 F 65567 b/l peri odantal cyst excision 145 44 21 II 65 66 65 69 68 74 68 68 70 78 69 69 73 136 139 140 142 140 148 132 129 128 136 126 129 130
Group B: ETT CUFF FILLED WITH NORMAL SALINE HEART RATE SYSTOLIC BLOOD PRESSURE
  
 
 
0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR 0HR 1HR 2HR 3HR 4HR 5HR 6HR 8HR 10HR 12HR 16HR 20HR 24HR T0TAL FENTANYL COUGH INCIDENT INEFFECTIVE TRIGGER
84 82 86 80 89 81 84 79 86 88 80 88 85 98 95 98 96 104 96 97 96 100 101 95 102 96 3 3 4 4 5 3 4 4 6 3 4 5 3 75 6 5
74 78 76 79 80 74 75 74 72 70 80 74 76 83 87 87 90 90 88 88 87 86 86 96 89 89 3 3 3 4 5 3 4 4 4 4 6 4 4 50 4 2
84 89 86 89 80 82 90 84 80 79 86 84 80 100 102 101 105 96 96 104 99 97 96 102 98 94 3 3 4 5 4 4 5 3 4 4 6 4 4 75 6 5
74 76 70 84 79 72 78 84 70 71 74 86 74 91 94 88 99 95 93 97 100 89 89 92 102 92 3 4 4 6 3 4 4 5 3 4 4 5 4 75 4 6
69 64 72 71 76 74 84 80 79 81 82 84 80 86 81 86 87 91 91 98 93 94 96 94 98 96 3 3 3 4 4 4 5 3 3 3 4 4 4 25 2 3
84 82 89 86 90 83 82 84 88 84 80 88 82 99 100 106 102 106 60 100 101 106 101 97 105 98 3 3 4 4 6 3 4 4 5 3 4 6 4 75 6 5
74 68 69 72 68 74 78 80 74 75 84 78 79 84 80 85 91 84 88 93 89 86 85 98 92 94 3 3 4 5 3 3 5 3 4 4 6 3 3 75 7 5
71 74 78 80 84 82 80 84 86 80 79 85 72 89 90 94 94 99 95 93 101 103 96 99 102 91 3 3 4 4 6 3 3 4 5 3 4 6 4 75 6 5
69 79 84 80 78 80 81 85 88 74 70 85 74 85 95 99 92 95 95 92 95 102 88 85 100 91 3 4 5 4 5 3 4 4 6 4 4 5 4 100 5 5
84 88 84 92 84 85 80 87 80 81 89 84 80 100 102 100 108 103 102 97 105 93 94 102 100 98 3 4 4 6 3 4 4 5 3 3 5 3 4 75 5 6
92 88 84 92 84 85 80 87 80 81 89 84 80 106 102 102 103 99 98 96 102 100 96 106 97 93 3 4 5 3 3 4 5 3 5 4 6 3 4 100 6 4
74 80 85 88 74 76 79 70 71 81 82 84 86 91 93 99 103 91 94 97 87 89 97 96 96 98 3 4 4 6 4 4 5 3 4 5 3 4 4 75 6 5
64 68 62 69 76 69 64 72 84 69 68 72 68 76 78 75 81 92 86 83 87 99 84 88 91 88 3 4 4 4 6 3 4 4 5 3 5 4 4 75 5 6
84 86 89 90 84 86 84 89 90 78 79 87 80 99 101 105 102 99 102 102 103 103 98 94 101 95 3 3 3 4 4 5 3 3 4 4 4 4 4 25 4 4
78 84 89 80 82 80 81 86 84 80 74 82 80 95 99 103 98 94 92 97 100 99 93 90 100 93 3 4 5 3 4 5 4 6 3 3 4 5 4 100 5 7
92 90 98 102 89 90 99 80 94 89 88 96 80 108 106 115 112 101 104 106 96 104 101 99 110 95 3 3 4 4 4 5 4 4 6 3 3 4 4 50 5 6
88 89 80 84 90 88 74 79 78 80 84 82 86 103 102 95 99 103 99 95 91 93 92 95 94 98 3 4 4 5 3 3 5 4 5 3 3 5 4 100 7 5
84 82 79 80 82 88 81 88 88 78 79 80 81 102 100 99 99 101 102 100 105 102 94 99 99 97 3 3 4 4 5 3 3 4 4 4 5 4 4 50 4 3
71 74 79 70 78 84 80 74 88 74 80 84 80 86 88 91 86 94 99 96 93 104 92 95 99 92 3 3 4 4 4 6 3 4 5 3 4 5 3 75 5 7
81 84 78 88 80 81 86 81 79 74 84 80 81 96 96 95 102 98 98 102 96 94 92 101 96 97 3 3 4 5 4 4 5 4 4 4 6 4 4 75 5 5
71 78 74 80 84 80 79 74 88 70 74 78 72 87 90 89 93 98 93 91 88 102 85 91 88 90 3 3 4 4 5 4 4 4 6 3 4 4 4 50 4 5
84 88 80 90 84 85 92 88 80 82 89 80 78 99 107 103 110 103 103 108 105 100 102 108 96 97 3 4 4 5 4 4 6 3 4 4 5 3 4 75 7 6
74 76 79 78 80 81 84 80 81 89 82 88 81 82 84 84 86 88 86 89 86 88 94 88 95 91 3 3 4 4 5 3 4 4 4 6 4 5 4 75 5 6
70 69 64 84 80 74 84 81 80 86 80 88 80 85 84 81 98 94 89 98 96 94 100 97 104 96 3 3 4 5 3 4 5 3 4 6 4 5 3 100 5 6
90 89 92 90 88 88 84 78 84 89 78 74 75 105 106 108 107 105 108 100 95 98 105 94 92 93 3 3 3 4 4 5 3 3 4 5 3 3 4 50 2 2
                              BEHAVIOUR PAIN SCALE                                          DIASTOLIC BLOOD PRESSURE MEAN ARTERIAL PRESSURE
